UBS/CALL/IDORSIA/3.502/0.5/20.09.24 Stock

Warrant

YIDIOU

CH1292037012

Market Closed - Swiss Exchange 11:20:00 2024-06-17 EDT
0.22 ^CHF	-4.35%

Current month	-40.54%
1 month	-37.14%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart IDORSIA LTD

Chart UBS/CALL/IDORSIA/3.502/0.5/20.09.24

Latest news about IDORSIA LTD

Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds	06-28	GL
Swiss Cantonal Court Approves Amendments to Idorsia's Convertible Bonds	06-26	MT
Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds	06-25	GL
Carmat: changes in corporate governance	06-25	CF

More news

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	IDORSIA LTD
Issuer	UBS
	YIDIOU
ISIN	CH1292037012
Date issued	2023-10-05
Strike	3.502 CHF
Maturity	2024-09-20 (83 Days)
Parity	2 : 1
Emission price	0.25 CHF
Emission volume	N/A
Settlement	physique
Currency	CHF

Technical Indicators

Highest since issue	0.75 CHF
Lowest since issue	0.19 CHF
Delta	0.45x
Omega	2.280
Premium	92.6x
Gearing	5.07x
Moneyness	0.5785
Difference Strike	1.476 CHF
Difference Strike %	+42.15%
Spread	0.06 CHF
Spread %	26.09%
Theoretical value	0.2000
Implied Volatility	192.93 %
Total Loss Probability	85.33 %
Intrinsic value	0.000000
Present value	0.2000
Break even	3.902 CHF
Theta	-0.02x
Vega	0x
Rho	0x

Company Profile

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

More about the company